(P133) Spinal Cord Dose Comparison With and Without Contrast Density Correction on CT Myelogram Simulations for Patients Treated With Stereotactic Body or Conventional Radiotherapy

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

These data suggest that the use of a CT myelogram with simulation significantly underestimates the spinal cord maximum and mean doses. The clinical significance of this finding is uncertain, and this study is limited by its small sample size. Density correction should be further investigated in a larger study, given the high doses used in SBRT and potential morbidity of spinal cord injury.

Sukhjeet S. Batth, MD, MS, Raymond Chiu, CMD, Nicholas Trakul, MD, PhD; USC Norris Cancer Center

PURPOSE/OBJECTIVES: Patients treated with stereotactic body radiotherapy (SBRT, also known as stereotactic ablative radiotherapy) or conventional RT to spinal targets often undergo a computed tomography (CT) simulation with a myelogram to accurately identify the spinal cord. Treatment planning algorithms use Hounsfield units and a CT density table to calculate radiation dose. Accuracy of these calculations may be improved by correcting for the contrast’s actual density, which is not present at the time of treatment delivery. We hypothesize that the spinal cord receives a higher radiation dose than calculated after correction of the contrast’s physical density.

MATERIALS AND METHODS: CT simulations with a myelogram for treatment of 10 spinal targets from nine patients were retrospectively reviewed. Seven of these targets were treated with SBRT, one was treated with intensity-modulated RT, and two were treated with three-dimensional conformal RT. The contrast from the myelogram was contoured in the treatment planning software, and the physical density was adjusted to 1 g/cm3. The uncorrected spinal cord maximum and mean doses were then compared with the doses after correction of the density. A two-tailed, paired t-test was used to compare the calculated doses.

RESULTS: The corrected spinal cord doses were all significantly higher than the uncorrected doses based on paired t-test for the maximum dose (P = .0073) and the mean dose (P = .00087). The mean maximum cord dose was 2,065 cGy and 2,077 cGy after correction. The mean of the average cord dose was 1,302 cGy and 1,315 cGy after correction.

CONCLUSIONS: These data suggest that the use of a CT myelogram with simulation significantly underestimates the spinal cord maximum and mean doses. The clinical significance of this finding is uncertain, and this study is limited by its small sample size. Density correction should be further investigated in a larger study, given the high doses used in SBRT and potential morbidity of spinal cord injury.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content